# Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC

> **NCT02394015** · — · COMPLETED · sponsor: **Grupo Español de Investigación en Cáncer de Ovario** · enrollment: 90 (actual)

## Conditions studied

- Ovarian Epithelial Cancer Recurrent

## Interventions

- **DRUG:** Trabectedin and Pegylated Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT02394015
- **Lead sponsor:** Grupo Español de Investigación en Cáncer de Ovario
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-06
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2020-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02394015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02394015, "Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02394015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*